Navigation Links
Vaccine triggers immune response, prevents Alzheimer's
Date:5/19/2008

A vaccine created by University of Rochester Medical Center scientists prevents the development of Alzheimers disease-like pathology in mice without causing inflammation or significant side effects.

Vaccinated mice generated an immune response to the protein known as amyloid-beta peptide, which accumulates in what are called amyloid plaques in brains of people with Alzheimers. The vaccinated mice demonstrated normal learning skills and functioning memory in spite of being genetically designed to develop an aggressive form of the disease.

The Rochester scientists reported the findings in an article in the May issue of Molecular Therapy, the journal of The American Society of Gene Therapy.

Our study demonstrates that we can create a potent but safe version of a vaccine that utilizes the strategy of immune response shaping to prevent Alzheimers-related pathologies and memory deficits, said William Bowers, associate professor of neurology and of microbiology and immunology at the Medical Center and lead author of the article. The vaccinated mice not only performed better, we found no evidence of signature amyloid plaque in their brains.

Alzheimers is a progressive neurodegenerative disease associated with dementia and a decline in performance of normal activities. Hallmarks of the disease include the accumulation of amyloid plaques in the brains of patients and the loss of normal functioning tau, a protein that stabilizes the transport networks in neurons. Abnormal tau function eventually leads to another classic hallmark of Alzheimers, neurofibrillary tangle in nerve cells. After several decades of exposure to these insults, neurons ultimately succumb and die, leading to progressively damaged learning and memory centers in the brain.

The mice that received the vaccines were genetically engineered to express large amounts of amyloid beta protein. They also harbored a mutation that causes the tau-related tangle pathology. Prior to the start of the vaccine study, the mice were trained to navigate a maze using spatial clues. They were then tested periodically during the 10-month study on the amount of time and distance traveled to an escape pod and the number of errors made along the way.

What we found exciting was that by targeting one pathology of Alzheimers amyloid beta we were able to also prevent the transition of tau from its normal form to a form found in the disease state, Bowers said.

The goal of the vaccine is to prompt the immune system to recognize amyloid beta protein and remove it. To create the vaccine, Bowers and the research group use a herpes virus that is stripped of the viral genes that can cause disease or harm. They then load the virus container with the genetic code for amyloid beta and interleukin-4, a protein that stimulates immune responses involving type 2 T helper cells, which are lymphocytes that play an important role in the immune system.

The research group tested several versions of a vaccine. Mice were given three injections of empty virus alone, a vaccine carrying only the amyloid beta genetic code, or a vaccine encoding both amyloid beta and interlueikin-4, which was found to be the most effective.

We have learned a great deal from this ongoing project, Bowers said. Importantly, it has demonstrated the combined strengths of the gene delivery platform and the immune shaping concept for the creation of customized vaccines for Alzheimers disease, as well as a number of other diseases. We are currently working on strategies we believe can make the vaccine even safer.

Bowers expects the vaccine eventually to be tested in people, but due to the number of studies required to satisfy regulatory requirements, it could be three or more years before human trials testing this type of Alzheimers vaccine occur.


'/>"/>

Contact: Michael Wentzel
Michael_Wentzel@urmc.rochester.edu
585-275-1309
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. Prostate Cancer Vaccine Looks Promising in Early Trial
2. AIDS Action Urges Everyone to Help End the AIDS Epidemic by Being Part of the Search for an HIV Vaccine
3. World AIDS Vaccine Day 2008
4. Chemotherapy might help cancer vaccines work
5. CDC Recommends Shingles Vaccine for Those Over 60
6. Dutch Authorize Manufacture of Vaccinogens New Cancer Vaccine; License Clears Path to European Production, Final FDA Trial
7. Many Moms Unwilling to Have Younger Daughters Get HPV Vaccine
8. Discovery to hasten new malaria treatments, vaccines for children
9. UMass Medical School researchers awarded pediatric HIV vaccine development grant
10. Experimental Cancer Vaccines Show Promise
11. Leading HIV researchers to collaborate on vaccine development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... MALVERN, PA (PRWEB) , ... ... ... Management ("CSM"), a Great Point Partners ("GPP") portfolio company, today announced it ... Clinical Supplies ("TCS"). TCS was previously a subsidiary of Chiltern International ...
(Date:12/5/2016)... ... December 05, 2016 , ... The new knee compression ... looking to buy neoprene knee sleeves for lifting and any sport that ... heavily on two main aspects to provide a higher quality knee sleeve performance. Firstly ...
(Date:12/5/2016)... ... December 05, 2016 , ... A newly released ... improves the reproducibility and accuracy of placing precordial electrodes with little cognitive effort ... the last 60 years, studies have shown that single electrode misplacement is one ...
(Date:12/4/2016)... ... December 03, 2016 , ... Houston ... the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine ... Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, ...
(Date:12/4/2016)... ... ... Responsible dental care hinges on regular brushing of the teeth. However, just brushing ... inspired an inventor from Las Vegas, Nev., to design the BRUSH PROPER. , ... bad techniques of brushing the teeth in order to prevent cavities," he said. "Children ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... 5, 2016  Sharn Anesthesia Inc. announced today that ... distribution partner for Salter Labs.  The company also received ... recognition of outstanding sales performance. Salter Labs ... anesthesia care, including the market gold standard ECO 2 ... distributor of the Parker Flex-Tip® Endotracheal Tube, which is ...
(Date:12/5/2016)... -- Sanovas, Inc., a life science asset holding ... its wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed ... - http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed ...
(Date:12/5/2016)... 5, 2016  Recently Zymo Research announced an ... known as Horvath,s Clock. Based on this technology, ... service to academic and biopharma scientific researchers to ... other than sperm. The service quantifies ... age versus chronological age following drug treatments and ...
Breaking Medicine Technology: